The clinical significance of serum chitinase 3‐like 1 in hepatitis B–related chronic liver diseases

Jiang, Zhibing; Wang, Shuwei; Jin, Jian-Cheng; Sheng, Ying; Chen, Zhigang; Zhu, Dedong; Xiao, Bingxiu; Hu, Yaoren; Qian, Yun-Song; Cai, Ting; Fu, Liyun

doi:10.1002/jcla.23200

Cited by 17 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CHI3L1 is considered to be an important pro-inflammatory mediator, as it is often elevated in both the serum and tissues of patients with inflammatory conditions 12 , 32 , including a range of liver diseases 33 . CHI3L1 is highly expressed in liver tissues and is induced in both acute and chronic liver injury in animal models 34 .…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stem cells alleviate experimental immune-mediated liver injury via chitinase 3-like protein 1-mediated T cell suppression

Liu

Pan

et al. 2021

Cell Death Dis

View full text Add to dashboard Cite

Liver diseases with different pathogenesis share common pathways of immune-mediated injury. Chitinase-3-like protein 1 (CHI3L1) was induced in both acute and chronic liver injuries, and recent studies reported that it possesses an immunosuppressive ability. CHI3L1 was also expressed in mesenchymal stem cells (MSCs), thus we investigates the role of CHI3L1 in MSC-based therapy for immune-mediated liver injury here. We found that CHI3L1 was highly expressed in human umbilical cord MSCs (hUC-MSCs). Downregulating CHI3L1 mitigated the ability of hUC-MSCs to inhibit T cell activation, proliferation and inflammatory cytokine secretion in vitro. Using Concanavalin A (Con A)-induced liver injury mouse model, we found that silencing CHI3L1 significantly abrogated the hUC-MSCs-mediated alleviation of liver injury, accompanying by weakened suppressive effects on infiltration and activation of hepatic T cells, and secretion of pro-inflammatory cytokines. In addition, recombinant CHI3L1 (rCHI3L1) administration inhibited the proliferation and function of activated T cells, and alleviated the Con A-induced liver injury in mice. Mechanistically, gene set enrichment analysis showed that JAK/STAT signalling pathway was one of the most significantly enriched gene pathways in T cells co-cultured with hUC-MSCs with CHI3L1 knockdown, and further study revealed that CHI3L1 secreted by hUC-MSCs inhibited the STAT1/3 signalling in T cells by upregulating peroxisome proliferator-activated receptor δ (PPARδ). Collectively, our data showed that CHI3L1 was a novel MSC-secreted immunosuppressive factor and provided new insights into therapeutic treatment of immune-mediated liver injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Mesenchymal stem cells alleviate experimental immune-mediated liver injury via chitinase 3-like protein 1-mediated T cell suppression

Liu

Pan

et al. 2021

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…The Omic study conducted by Huang et al has shown that CHI3L1 is specifically expressed in the liver 5 . Our previous study has shown that CHI3L1 has better performance in diagnosing liver fibrosis than other noninvasive methods in chronic hepatitis B patients 6 . In some cancers such as gastrointestinal tumors, ovarian cancer, melanoma, urinary system tumors, lung cancer, and glioblastoma, CHI3L1 can help to distinguish patients between a good prognosis and poor prognosis 7 .…”

Section: Introductionmentioning

confidence: 99%

“… 5 Our previous study has shown that CHI3L1 has better performance in diagnosing liver fibrosis than other noninvasive methods in chronic hepatitis B patients. 6 In some cancers such as gastrointestinal tumors, ovarian cancer, melanoma, urinary system tumors, lung cancer, and glioblastoma, CHI3L1 can help to distinguish patients between a good prognosis and poor prognosis. 7 Studies have shown that deficiency of CHI3LI can ameliorate liver fibrosis and that upregulation of CHI3L1 can exaggerate HCC cells proliferation, invasion, and migration.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic value of serum Chitinase 3‐like protein 1 in hepatocellular carcinoma

Wang

Chen

Jin

et al. 2022

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

The serum Chitinase 3‐like protein 1 (CHI3L1) protein level can distinguish the stages of liver fibrosis to a great extent. However, the diagnostic and prognostic significance of serum CHI3L1 in hepatocellular carcinoma (HCC) is not clarified. To evaluate the diagnostic and prognostic value of CHI3L1 in HCC, a total of 128 HCC patients treated in the HwaMei Hospital, University of Chinese Academy of Sciences, from December 2018 to April 2020 were collected retrospectively. Matched age and gender subjects, 40 patients with liver cirrhosis, 40 patients with chronic hepatitis, and 40 healthy subjects were enrolled in the control group. The relevant clinical laboratory and examination data and the overall survival time (OS) of the HCC patients were collected. The serum CHI3L1 expression level is related to α‐fetoprotein (AFP), tumor‐node‐metastasis (TNM) stage, maximum tumor diameter, liver cirrhosis, and HCC patient's OS (p < 0.05). The area under the curve (AUC) of CHI3L1 was 0.7875 with the cutoff value of 91.36 ng/ml. Combining the serum CHI3L1 and α‐fetoprotein (AFP) by a binary logistic regression model can increase the diagnostic sensitivity to 97.5%. Multivariate Cox regression analysis indicated that CHI3L1 is an independent prognostic factor in patients with HCC.

show abstract

“…A prior meta-analysis that included nine articles published before 2018 evaluated the diagnostic value of serum YKL-40 (CHI3L1) for liver fibrosis stage. However, Zhang and colleagues [ 68 ] concluded that its diagnostic value for significant and advanced fibrosis was limited. They included patients undergoing kidney transplant in their study, and the specificity for significant fibrosis was as low as 0.53, which was poorer than the results of specificity in our study [ 69 ].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Serum Chitinase-3-Like Protein 1 for Liver Fibrosis: A Meta-analysis

Huang

Zhuang

Yang

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Background. Serum chitinase-3-like protein 1 (CHI3L1) is a promising marker for diagnosing liver fibrosis. This meta-analysis was carried out to assess the diagnostic performance of serum CHI3L1 for the estimation of liver fibrosis. Methods. Systematic searches were performed on PubMed, Embase, Web of Science, Scopus, the Cochrane Library, Google Scholar, Sinomed, the China National Knowledge Infrastructure (CNKI), the Chinese Medical Journal Database, and the Wanfang databases for available studies. The primary studies were screened strictly according to inclusion and exclusion criteria, and sensitivity, specificity, and other measures of accuracy of serum CHI3L1 for evaluating liver fibrosis were pooled with 95% confidence intervals. I 2 was calculated to assess heterogeneity, and sources of heterogeneity were explored by subgroup analysis. Deeks’ test was used to assess for publication bias, and likelihood ratio was used to determine posttest probability. Results. Our research integrated 11 articles, accounting for 1897 patients older than 18 years old. The pooled sensitivity and specificity for significant fibrosis, advanced fibrosis, and cirrhosis were 0.79 and 0.82 with an area under the receiver operating characteristic curve (AUC) of 0.85, 0.81 and 0.83 with an AUC of 0.91, and 0.72 and 0.74 with an AUC of 0.85, respectively. Random-effects models were used to assess for significant heterogeneity, and subgroup analysis showed that age and aetiology of included patients were likely sources of heterogeneity. No potential publication bias was found for serum CHI3L1 in the diagnosis of significant fibrosis, advanced fibrosis, or cirrhosis, and posttest probability was moderate. Conclusion. Measurement of serum CHI3L1 is a feasible diagnostic tool for liver fibrosis.

show abstract

The clinical significance of serum chitinase 3‐like 1 in hepatitis B–related chronic liver diseases

Cited by 17 publications

References 31 publications

Mesenchymal stem cells alleviate experimental immune-mediated liver injury via chitinase 3-like protein 1-mediated T cell suppression

Mesenchymal stem cells alleviate experimental immune-mediated liver injury via chitinase 3-like protein 1-mediated T cell suppression

Diagnostic and prognostic value of serum Chitinase 3‐like protein 1 in hepatocellular carcinoma

Diagnostic Value of Serum Chitinase-3-Like Protein 1 for Liver Fibrosis: A Meta-analysis

Contact Info

Product

Resources

About